Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-driven chemotherapy in advanced NSCLC
NCT01648517Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2012
- Primary completion
- Jun 2015
- Countries
- 1
- Sponsor
- Yonsei University
- Modality
- DNA Intercalators/Alkylators
- Conditions
- non-small cell lung carcinoma (NSCLC)
01
Overview
Phase 2, randomised, open-label trial of docetaxel, vinorelbine, gemcitabine and carboplatin in non-small cell lung carcinoma (NSCLC), sponsored by Yonsei University. Started Jul 2012; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
This is a prospective phase II trial, in patients with unresectable or metastatic NSCLC using chemotherapy regimens which will be defined according to the mRNA expression of ERCC1 and RRM1 of the tumor cells.
Beyond the preview
Go deeper on NCT01648517.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01648517.